Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia
Autore:
George, TP; Ziedonis, DM; Feingold, A; Pepper, WT; Satterburg, CA; Winkel, J; Rounsaville, BJ; Kosten, TR;
Indirizzi:
Yale Univ, Sch Med, Dept Psychiat, Div Substance Abuse, New Haven, CT 06519 USA Yale Univ New Haven CT USA 06519 Substance Abuse, New Haven, CT 06519 USA Connecticut Mental Hlth Ctr, Dual Diag & Smoking Res Program, New Haven, CT USA Connecticut Mental Hlth Ctr New Haven CT USA Program, New Haven, CT USA Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Div Addict Psychiat, Piscataway, NJ 08854 USA Univ Med & Dent New Jersey Piscataway NJ USA 08854 scataway, NJ 08854 USA
Titolo Testata:
AMERICAN JOURNAL OF PSYCHIATRY
fascicolo: 11, volume: 157, anno: 2000,
pagine: 1835 - 1842
SICI:
0002-953X(200011)157:11<1835:NTPAAA>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
CIGARETTE-SMOKING; STARTLE REFLEX; CLOZAPINE; DEPENDENCE; SYMPTOMS; WITHDRAWAL; DISEASE; THERAPY; SMOKERS; TOBACCO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Life Sciences
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: George, TP Yale Univ, Sch Med, Dept Psychiat, Div Substance Abuse, 34 Pk St,Rm S-109,New Haven, CT 06519 USA Yale Univ 34 Pk St,Rm S-109 New Haven CTUSA 06519 CT 06519 USA
Citazione:
T.P. George et al., "Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia", AM J PSYCHI, 157(11), 2000, pp. 1835-1842

Abstract

Objective: Schizophrenic patients have high rates of cigarette smoking. The authors compared the outcomes of two group psychotherapy programs for smoking cessation in patients with schizophrenia or schizoaffective disorder who were also treated with the nicotine transdermal patch and with either atypical or typical antipsychotic medications. Method: Forty-five subjects were randomly assigned to 1) the group therapyprogram of the American Lung Association (N=17) or 2) a specialized group therapy program for smokers with schizophrenia (N=28) that emphasized motivational enhancement, relapse prevention, social skills training, and psychoeducation. All subjects participated in 10 weeks of treatment with the nicotine transdermal patch (21 mg/day) and 10 weekly group therapy sessions andcontinued to receive their prestudy atypical (N=18) or typical (N=27) antipsychotic medications. Outcome variables included treatment retention, rateof smoking abstinence, and expired-breath carbon monoxide level. Results: Smoking abstinence rates did not differ in the two group therapy programs. However, atypical antipsychotic agents, in combination with the nicotine transdermal patch, significantly enhanced the rate of smoking cessation (55.6% in the atypical agent group versus 22.2% in the typical group),which was reflected by a significant effect of atypical versus typical agents on carbon monoxide levels. Risperidone and olanzapine were associated with the highest quit rates. Conclusions: The results suggest that I)smoking cessation rates with the nicotine transdermal patch are modest in schizophrenia, 2) specialized grouptherapy for schizophrenic patients is not significantly different from American Lung Association group therapy in its effect on smoking cessation, and 3) atypical agents may be superior to typical agents in combination with the nicotine transdermal patch for smoking cessation in schizophrenia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 16:41:29